ArticleBlood cancer journal2025

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.